
Neuralgene is a biotechnology company with its’ flagship gene therapy platform a neurotropic AAV gene therapy designed to treat the neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS). Neuralgene has partnered with Helica Labs to begin production of several AAV gene therapies in its' R&D pipeline for the treatment of other neural diseases such as Parkinson’s, Adronoleukodystrophy and ALS. Neuralgene has initiated initial human testing in it’s gene therapies for ALS and ALD.